RSS

Genmab

Clinical-stage biopharmaceutical company, Immatics Biotechnologies, has entered into a research collaboration and licence agreement with international biotech company, Genmab, to develop next generation bispecific cancer immunotherapies. Read more

News

Following a planned review, the Data Monitoring Committee (DMC) has recommended termination of the Phase Ib/II study of daratumumab in combination with atezolizumab versus atezolizumab monotherapy in patients with previously treated NSCLC Read more

News

Biotechnology company, Genmab, has announced that the FDA has approved the use of DARZALEX (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) for the treatment of patients with newly diagnos Read more

News

Novartis plans to transition the use of its treatment for certain chronic lymphocytic leukaemia (CLL), Arzerra (ofatumumab), from commercial availability to limited availability via compassionate use programmes in all markets except the US. Read more

News

A new strategy to tackle the issue of long-term treatment efficacy in cancer patients has been developed by researchers from the Netherlands Cancer Institute in collaboration with international biotechnology company, Genmab. Read more

News

Genmab’s licensing partner, Janssen Biotech, has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for the use of daratumumab (DARZALEX) in front line multiple myeloma. Read more

Technology

Genmab has announced that the FDA has approved the use of DARZALEX (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies. Read more

News

Genmab has announced that its collaboration partner for daratumumab, Janssen Biotech, has decided to not initiate stage 2 of the Phase II study. Read more

News

As October is Breast Cancer Awareness month EPM has put together a list of medical developments and partnerships in the pharmaceutical sector that are helping to treat cancer Read more

Opinion

Genmab's licensing partner Janssen Biotech has initiated a rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for daratumumab. Read more

News

BioNTech and Genmab have collaborated to research, devlop and commercialise multiple bispecific antibodies for cancer immunotherapy. Read more

News